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Fibroblasts Show More Potential as Target Cells
than Keratinocytes in COL7A1 Gene Therapy of
Dystrophic Epidermolysis Bullosa
Maki Goto1, Daisuke Sawamura1, Kei Ito1, Masataka Abe1, Wataru Nishie1, Kaori Sakai1, Akihiko Shibaki1,
Masashi Akiyama1 and Hiroshi Shimizu1
Dystrophic epidermolysis bullosa (DEB) is an inherited blistering skin disorder caused by mutations in the type
VII collagen gene (COL7A1). Therapeutic introduction of COL7A1 into skin cells holds significant promise for
the treatment of DEB. The purpose of this study was to establish an efficient retroviral transfer method for
COL7A1 into DEB epidermal keratinocytes and dermal fibroblasts, and to determine which gene-transferred
cells can most efficiently express collagen VII in the skin. We demonstrated that gene transfer using a
combination of G protein of vesicular stomatitis virus-pseudotyped retroviral vector and retronectin introduced
COL7A1 into keratinocytes and fibroblasts from a DEB patient with the lack of COL7A1 expression. Real-time
polymerase chain reaction analysis of the normal human skin demonstrated that the quantity of COL7A1
expression in the epidermis was significantly higher than that in the dermis. Subsequently, we have produced
skin grafts with the gene-transferred or untreated DEB keratinocytes and fibroblasts, and have transplanted
them into nude rats. Interestingly, the series of skin graft experiments showed that the gene-transferred
fibroblasts supplied higher amount of collagen VII to the new dermal–epidermal junction than the gene-
transferred keratinocytes. An ultrastructural study revealed that collagen VII from gene-transferred cells formed
proper anchoring fibrils. These results suggest that fibroblasts may be a better gene therapy target of DEB
treatment than keratinocytes.
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INTRODUCTION
Type VII collagen, a non-fibrillar collagen, is a major
component of anchoring fibril loop structures beneath the
epidermal basement membrane (Uitto et al., 1992; Burgeson,
1993). Cloning of collagen VII cDNA demonstrated a primary
sequence of 2,944 amino acids and the basic organization of
the functional domains (Christiano et al., 1994a). Subsequent
genomic cloning has highlighted the structural organization
of the collagen VII gene (COL7A1) (Christiano et al., 1994b).
This cloning information has enabled genomic DNA
sequence analysis of COL7A1 and has demonstrated that
mutations within COL7A1 are associated with the dystrophic
forms of epidermolysis bullosa (DEB). DEB comprises a group
of mechanobullous diseases characterized by cutaneous
fragility with a tendency to form sub-basal lamina densa
blisters (Christiano et al., 1993; Pulkkinen and Uitto, 1999;
Chen et al., 2002a). In addition, targeted disruption of
COL7A1 in a mouse model demonstrated an almost identical
phenotype to DEB in humans (Heinonen et al., 1999). These
results indicate that collagen VII is of critical importance for
dermal–epidermal adhesion.
Approximately 300 distinct COL7A1 mutations have been
identified in DEB patients so far. Therapeutic introduction of
COL7A1 into skin cells is a promising treatment of DEB.
Despite the relatively large size of COL7A1, the cDNA of
which is still 9 kb makes gene transfer relatively problematic,
and several methods including lentivirus- (Chen et al.,
2002b), retrovirus- (Baldeschi et al., 2003) and fC31
integrase-based approaches (Ortiz-Urda et al., 2002) have
attempted to transfer COL7A1 into keratinocytes. These
studies used keratinocytes as target cells as collagen VII has
been reported to be mainly synthesized and secreted by
keratinocytes and to lesser extent by fibroblasts (Ryynanen
et al., 1992). However, application of gene-transferred DEB
fibroblasts into the skin restored collagen VII expression in
the dermal–epidermal junction (Ortiz-Urda et al., 2003;
Woodley et al., 2003). In addition, using an intradermal
injection of lentivirus with COL7A1 induced the expression
of collagen VII in fibroblasts and endothelial cells, resulting in
collagen VII accumulation in the grafted DEB skin on the host
animal (Woodley et al., 2004).
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In this study, we have established a retroviral method to
transfer COL7A1 into DEB keratinocytes and fibroblasts.
Next, we produced the skin grafts with gene-transferred
keratinocytes or fibroblasts, and transplanted them into nude
rats. Examination of collagen VII graft expression revealed
that gene-transferred fibroblasts assembled more collagen VII
in the form of anchoring fibrils beneath the basement
membrane than gene-transferred keratinocytes. We conclude
that fibroblasts are a more ideally suited target for COL7A1
gene transfer than keratinocytes using retroviral gene therapy
for the treatment of DEB.
RESULTS
Successful transfer COL7A1 using retroviral systems
We employed two retroviral vectors, pLIXN and pDON-AI,
and full-length COL7A1 cDNA was inserted into the
retroviral vectors to generate plasmids termed pLI-COL
and pDON-COL, respectively (Figure 1). Also, we created
pDON(D) by removing the SV-40 promoter and Neo gene
from pDON-AI and constructed a retroviral vector with
COL7A1 cDNA pDON(D)-COL (Figure 1). Several series
of preliminary experiments demonstrated that retronectin
(TAKARA) increased attachment of virus to keratinocytes and
fibroblasts. Also, use of plasmid G protein of vesicular
stomatitis virus (pVSV-G) (Pantropic System; Clontech, Palo
Alto, CA) enabled concentration of viral particles by ultra-
centrifugation, resulting in an increase of transfer efficacy.
After transfection of plasmids pLI-COL, pDON-COL, and
pDON(D)-COL to 293 packaging cells, the culture media
were collected. The virus titers (mean7SD 106/ml) of pLI-
COL, pDON-COL, and pDON(D)-COL were 1.1þ0.35,
1.6þ0.46, and 2.7þ 0.55, respectively.
We transferred COL7A1 into cultured DEB keratinocytes
and fibroblasts using the retroviral system. Transfection
experiments showed that retroviral methods using pLI-COL
and pDON-COL failed to introduce COL7A1 to DEB cells
(data not shown). Plasmid pDON(D)-COL with the VSV-G
system allowed a greater gene transfer after further concen-
tration of the virus particles increased the transfer rate
(Figure 2). Immunostaining revealed that the transfer rates
in DEB keratinocytes and fibroblasts were almost the same
(Figures 2 and 3a), and immunoblotting demonstrated that
the amount of collagen VII in their culture media was also
identical (Figure 3b). The average copy number per cell of the
COL7A1 cDNA was evaluated by Southern blot analysis
of genomic DNA extracted from the transduced cells. The
result indicated that the intensities of 7.2 kb band from the
integrated cDNA were the same in treated keratinocytes and
fibroblasts, suggesting that integration copies for keratino-
cytes and fibroblasts was almost equal (Figure 3c). The copy
number was estimated 2–3 by comparing with a serial
dilution standard (data not shown).
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Figure 1. Schematic representation of retroviral COL7A1 expression
vectors. We employed two retroviral vectors, pLIXN (Clontech) and pDON-AI
(Takara, Japan), and full-length COL7A1 cDNA was inserted into the retroviral
vectors to generate plasmids pLI-COL and pDON-COL, respectively. A
pDON(D) vector was created by removing the SV-40 promoter and Neo gene
from pDON-AI and COL7A1 cDNA constructed retroviral vector made
termed pDON(D)-COL. These vectors harbor long terminal repeat (LTR)
derived from mouse moloney leukemia virus (MMLV) and human cytome-
galovirus (HCMV). The internal ribosome entry site (IRES) enables expression
of two unrelated reading frames from a single transcription unit. c: packaging
signal.
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Figure 2. Successful gene transfer of COL7A1 into DEB fibroblasts and
keratinocytes using retroviral systems. COL7A1 was transferred into DEB
fibroblasts and keratinocytes using the retroviral systems. Immunostaining
revealed that the transfer rates in DEB keratinocytes and fibroblasts were
almost equal. The concentration of virus particles (by 10 or 50 times) using the
VSV-G system improves the transfer rate. The values were represented the
mean7SD of six individual samples.
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Figure 3. Corrective gene transfer of the COL7A1 into DEB fibroblasts and
keratinocytes. (a) Immnostaining showed that the gene-transfected DEB
keratinocytes Kera (þ ) and fibroblasts Fib (þ ) expressed collagen VII,
whereas no expression was found in either the untreated keratinocytes Kera
() or fibroblasts Fib (). Nuclei were counterstained with propidium iodide.
(b) Western blot analysis demonstrated that the amount of transgene product
in culture medium was almost the same between keratinocytes and
fibroblasts. (c) Southern blot analysis of genomic DNA extracted from the
transduced cells showed that the COL7A1 cDNA integration copies for
keratinocytes and fibroblasts were almost equal.
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In vivo COL7A1 expression in epidermis is higher than
that in dermis
To determine the COL7A1 expression level in the epidermis
and dermis in vivo, we separated the epidermis from the
dermis, and measured COL7A1 mRNA levels using real-time
PCR. Real-time PCR demonstrated that the COL7A1-specific
signal (per RNA) of the epidermis was higher than that of
the dermis by 3.2-fold (Figure 4). Comparison of the total
RNA amounts from the epidermis and dermis in the same
area of the excised normal skin showed that the amount
from the dermis was higher than that from the epidermis by
3.4-fold (Figure 4). Thus, the quantity of COL7A1 expression
in epidermis was significantly higher than that in dermis
in vivo.
Gene-transferred fibroblasts can supply more collagen VII
to the basement membrane zone than gene-transferred
keratinocytes
We transplanted the gene-transferred DEB keratinocytes and
fibroblasts into the wound of nude rats, and then observed
COL7A1 deposition 3, 6, and 9 weeks after transplantation.
In the skin graft with gene-transferred keratinocytes and
untreated fibroblasts, the COL7A1 deposition was detectable
in the basement membrane zone at 3 week and maintained
this expression at least until 9 weeks (Figure 5). However, we
found a greater accumulation of collagen VII in dermal–
epidermal junction of the grafts using untreated keratinocytes
and gene-transferred fibroblasts 3 weeks after transplantation.
Furthermore, DEB fibroblasts transfected with COL7A1
demonstrated more dermal–epidermal junction collagen VII
staining than COL7A1-transfected DEB keratinocytes/un-
treated fibroblast (Figure 5) from 6 to 9 weeks. The grafts of
DEB keratinocytes and fibroblasts as controls demonstrated
no deposition (Figure 5). Semiquantification of COL7A1
deposition in basement membrane zone in each point
showed DEB fibroblasts with COL7A1 can supply higher
amount of collagen VII to the basement membrane zone than
DEB keratinocytes with COL7A1 (Figure 6). Significant
differences were found between the keratinocytes and
fibroblasts samples at 3W and 9W points.
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Figure 4. In vivo COL7A1 expression in the epidermis is higher than that in
the dermis. We measured COL7A1 mRNA levels in the epidermis (Epi) and
dermis (Derm) in vivo. Real-time PCR demonstrated that the COL7A1-specific
signal (per RNA) of the epidermis was higher than that of the dermis.
Comparison of the total RNA amounts from the epidermis and dermis in the
same area of the excised normal skin showed that the amount from the dermis
was higher than that from the epidermis. The COL7A1 mRNA expression and
total RNA amounts were expressed as an arbitrary scale. The values were
represented the mean7SD from three separate samples. *Po0.01, significant
difference.
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Figure 5. Gene-transferred fibroblasts can supply more collagen VII to the
sub-basement membrane zone than gene-transferred keratinocytes. We
transplanted gene-transferred DEB keratinocytes and DEB fibroblasts to nude
rats wounded back skin, and observed COL7A1 deposition by immuno-
histochemistry at 3, 6, and 9 weeks after transplantation. The skin graft with
gene-transferred keratinocytes and untreated fibroblasts (Kera 3W, Kera 6W,
Kera 9W) started dermal–epidermal junction collagen VII deposition at 3
week and maintained it until 9 weeks. A greater accumulation of collagen VII
in dermal–epidermal junction of the grafts using untreated keratinocytes and
gene-transferred fibroblasts was found 3 weeks after transplantation (Fib 3W).
The DEB fibroblasts transfected with COL7A1 demonstrated more dermal–
epidermal junction collagen VII staining than COL7A1-transfected DEB
keratinocytes/untreated fibroblast from 6 to 9 weeks (Fib 6W, Fib 9W). The
control DEB keratinocyte and fibroblast cell grafts (Cont 3W, Cont 6W, Cont
9W) demonstrated no deposition. Arrowheads define the limit between the
dermis and epidermis.
5,000
4,000
3,000
2,000
1,000
3W 6W 9W
Time after transplantation
CO
L7
A1
 
de
po
sit
io
n 
in
de
x
0
*
*
K
F
C
Figure 6. Semiquantification of COL7A1 deposition in basement membrane
zone. We transplanted gene-transferred DEB keratinocytes and DEB
fibroblasts to nude rats wounded back skin, and observed COL7A1 deposition
by immunohistochemistry at 3, 6, and 9 weeks after transplantation. To
semiquantify COL7A1 deposition in basement membrane zone, we measured
fluorescence intensity (arbitrary scale) in basement membrane zone at
10 areas at each point and the COL7A1 deposition index was expressed as
the mean7SD from the 10 values. K: the skin graft with gene-transferred
keratinocytes and untreated fibroblasts; F: the graft with untreated keratino-
cytes and gene-transferred fibroblasts grafts; C: the graft with untreated
keratinocyte and untreated fibroblasts. *Po0.01, significant difference.
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Collagen VII released from gene-transferred cells forms
ultrastructurally normal anchoring fibrils
We examined the ultrastructural formation of anchoring
fibrils in the graft. The grafts with both gene-transferred
keratinocytes and fibroblasts demonstrated filamentous loop
structures just beneath the lamina densa, which were
corresponding to anchoring fibrils (Figure 7). We could not
see any filamentous structures in control (untransfected)
samples without COL7A1.
DISCUSSION
The developments in cloning the basement membrane
protein genes have allowed the identification of the causative
genes/proteins harboring the mutations responsible for this
group of epidermolysis bullosa diseases (Uitto and Pulkkinen,
2001). We can now make good estimations about the
prognosis and severity of these diseases with profound
beneficial effects on genetic counseling and DNA-based
prenatal diagnosis. However, patients most frequently desire
an appropriate therapy for epidermolysis bullosa. Corrective
transfer of the COL7A1 gene back into the skin cells is a
promising treatment of DEB.
The previous Northern hybridization study revealed a high
level of COL7A1 mRNA expression in cultured epidermal
keratinocytes, whereas the expression was lower in cultured
dermal fibroblasts (Ryynanen et al., 1992). These results
indicate that epidermal keratinocytes and dermal fibroblasts
express the collagen VII, but also suggest that epidermal
keratinocytes are the primary source of collagen VII in
developing human skin. Many investigators have utilized
keratinocytes as the target cells of DEB gene therapy. Several
methods including viral- (Ghazizadeh and Taichman, 2000)
and non-viral-mediated transduction (Vogel, 2000) have
been reported for in vivo and ex vivo gene transfer into
keratinocytes. COL7A1 cDNA was recently transferred into
cultured DEB keratinocytes using some methods including
lentivirus- (Chen et al., 2002b), retrovirus- (Baldeschi et al.,
2003) and fC31 integrase-based approaches (Ortiz-Urda
et al., 2002). The corrected DEB keratinocytes expressed the
recombinant collagen VII and restored the in vivo synthesis of
anchoring fibrils after implantation, demonstrating the
feasibility of gene transfer using DEB keratinocytes. We also
succeeded in transferring the COL7A1 into in vivo keratino-
cytes using the naked DNA method (Sawamura et al., 2002)
although the COL7A1 transfer efficacy was lower than the
above ex vivo method.
Many gene therapy protocols have already utilized retro-
viral vectors for clinical practices. In this study, we also
showed a retroviral vector could transfer the 9 kb COL7A1
cDNA into DEB keratinocytes. Another group has succeeded
in transducing COL7A1 gene to keratinocytes using
a retroviral plasmid containing the Neo selection gene
(Baldeschi et al., 2003). They showed that transduction
efficacies to primary keratinocytes were 40 and 83–93% by
retroviral vectors pLSRS-Ires-zero and pMSCV, respectively.
However, the use of similar plasmids is not possible to
efficiently introduce this gene into keratinocytes in our
experiments. In our system, the efficacy was about 30%,
which was lower than those in previous report. This study, as
far as we know, has been the first to try a retronectin retro-
viral targeting system for keratinocytes. Retronectin is a
recombinant peptide, which consists of three functional
fibronectin domains and significantly enhances retrovirus-
mediated gene transduction into mammalian cells. Our data
showed that addition of retronectin increased transfer
efficacy in keratinocytes by 3-fold (data not shown),
indicating that retronectin is indeed efficient in this keratino-
cyte/retroviral system.
Some groups have succeeded in transferring this gene into
keratinocytes as mentioned above. On the other hand,
cutaneous injection of the DEB fibroblasts transduced using
fC31 integrase-based approach also restores collagen VII
deposition along the dermal–epidermal junction (Ortiz-Urda
et al., 2003). Also, gene-corrected DEB fibroblasts and
normal human fibroblasts alone could supply type VII
collagen deposition at the basement membrane zone in vivo
(Woodley et al. 2003), and this implies a possibility that
normal cultured human dermal fibroblasts are injected
intradermally into recesive dystrophic epidermolysis bullosa
patients’ skin. Moreover, intradermal injection of lentiviral
vector with COL7A1 increased collagen VII expression in
fibroblasts and endothelial cells, resulting in stronger depo-
sition of collagen VII along the basement membrane zone
anchoring fibrils as seen by electron microscopy (Woodley
et al., 2004). This study also introduced the COL7A1 gene
into DEB fibroblasts using the retroviral method and the
consequent collagen VII assembly beneath the basement
membrane of the fibroblast containing graft.
In this study, we compared dermal fibroblasts and
epidermal keratinocytes as efficient target recipient cells for
the collagen VII transgene product. After retroviral introduc-
tion of COL7A1, the transfer efficacy and the amount of
collagen VII in the cultured keratinocytes media supernatant
are almost the same as those of fibroblasts. Interestingly, a
series of skin graft experiments first demonstrated that gene-
transfected fibroblasts more efficiently assembled collagen
VII into the dermal–epidermal junction than the gene-
transferred keratinocytes. Previous Northern blotting ana-
lysis revealed higher level of COL7A1 mRNA expression in
cultured epidermal keratinocytes than fibroblasts (Ryynanen
Kera Fib Cont
Figure 7. Collagen VII released from gene-transferred cells forms anchoring
fibrils similar to normal skin. We examined the ultrastructural formation
of anchoring fibrils in the grafts. The grafts with the gene-transferred
keratinocytes (Kera) or the gene-transferred fibroblasts (Fib) demonstrated
cross-banded, filamentous structures sometimes forming semicircular loops
immediately beneath the lamina densa, corresponding to anchoring fibrils,
whereas we failed to identify these filamentous structures in control without
COL7A1 transfection (Cont).
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et al., 1992). This study utilized real-time PCR technique and
confirmed that the epidermis produced much more collagen
VII than the dermis in vivo. If gene-transferred fibroblasts
and keratinocytes express similar amounts of type VII
collagen also in vivo, the fibroblasts may have a better
ability to supply type VII collagen to the basement membrane
than the keratinocytes.
It is evident that expression of recombinant collagen VII
is driven by heterologous promoters, which escape the
regulatory mechanisms that govern the expression of
endogenous collagen VII in the different cell types. Also,
keratinocytes have been preferred because of the possibility
they offer of targeting stem cells and compared to keratino-
cytes, fibroblasts rapidly senesce in vivo (Krueger, 2000).
However, fibroblasts are more robust and less susceptible
to growth arrest and differentiation than epidermal keratino-
cytes (Ortiz-Urda et al., 2003). Furthermore, genetically
engineered fibroblasts have had their use explored for
therapeutic applications including visceral and cutaneous
implantation to supply gene products to circulation (Roth
et al., 2001). Given the above combined factors, it is
proposed that fibroblasts may be potentially more feasible
and a better target of DEB gene therapy than keratinocytes.
MATERIALS AND METHODS
Cell culture
Primary keratinocytes were isolated and grown in the presence of an
irradiated 3T3 feeder layer (Rheinwald and Green, 1975). Briefly,
keratinocytes, which were obtained from skin biopsy of a DEB
patient and healthy controls, were cultured on feeder layers of
mitomycin C-treated mouse 3T3 fibroblasts in DMEM: Ham’s F-12
(3:1) supplemented with 10% fetal calf serum (FCS), 5mg/ml insulin,
10 ng/ml epidermal growth factor, 0.4 mg/ml hydrocortisone, and
8 ng/ml cholera toxin. The DEB patient was diagnosed as the most
severe subtype, and Hallopeau–Siemens type showed no COL7A1
expression in the skin and harbored heterozygous premature stop
codon mutations 1474del8 and 5818delC. Fibroblasts were also
obtained from skin biopsy from the DEB patient and healthy
controls, and were cultured in DMEM with 10% FCS. Packaging
cells amphopack-293 and GP2-293 (Clontech, Palo Alto, CA) were
maintained in DMEM with 10% FCS, 2 mM glutamine, and 2 mM
sodium pyruvate.
Informed consents were obtained from all individual subjects in
this study. The protocols were approved by the Ethical Committee at
Hokkaido University Graduate School of Medicine. This study was
conducted according to the Declaration of Helsinki Principles.
Intrinsic expression of collagen VII in control keratinocytes and
fibroblasts
Human skin was obtained from normal volunteers, and treated with
10 mg/ml dispase for 3 hours at 371C to separate the epidermis from
the dermis. The epidermal and dermal sheets were minced and total
RNA was extracted using an RNeasy RNA extraction kit (Qiagen,
Hilden, Germany). First-strand cDNA was synthesized with reverse
transcriptase (Life Sciences Inc., St Petersburg, FL) using an oligo-dT
primer. Assays-on-DemandTM Products for COL7A1 and GAPDH
were purchased from Applied Biosystems (Foster City, CA). The 50 ml
reaction in each well contained 1ml of total cDNA, 300 nM
sequence-specific primers, and 200 nM dual-labeled fluorogenic
probe with 1 U of Taqman Universal PCR master mix (Applied
Biosystems). A negative control PCR without template and a positive
PCR control with a template of known amplification were included
in each assay. The samples underwent the following stages: stage 1,
501C for 2 minutes; stage 2, 951C for 10 minutes; and stage 3, 951C
for 15 seconds, followed by 601C for 1 minutes. Stage 3 was repeated
45 times. Gene-specific products were measured by means of
an ABI Prism 7700 sequence detection system (Perkin-Elmer
Applied Biosystems, Foster City, CA) continuously for 45 cycles.
The COL7A1-specific signal was normalized by constitutively
expressed GAPDH and expressed as arbitrary scale.
Construction of retroviral COL7A1 expression vectors and
transfection
Human full-length COL7A1 cDNA was constructed from several
overlapping cDNA clones (Sawamura et al., 2002). We employed
two retroviral vectors, pLIXN (Clontech) and pDON-AI (Takara,
Otsu, Japan), and full-length COL7A1 cDNA was inserted into the
retroviral vectors to generate plasmids termed pLI-COL and
pDON-COL, respectively (Figure 1). Also, we created pDON(D) by
removing the SV-40 promoter and Neo gene from pDON-AI and
constructed a retroviral vector with COL7A1 cDNA pDON(D)-COL
(Figure 1). The recombinant retroviruses were produced by
transfecting the retroviral plasmids into the amphotropic ampho-
pack-293 packaging cells (Clontech) using calcium-phosphate co-
precipitation. In addition, we tried VSV-G-pseudotyped retrovirus
vectors. The retroviral plasmids and plasmid pVSV-G were
cotransfected into pantropic GP2-293 packaging cells (Clontech).
The viral particles were recovered from the cell culture medium
48 hours later and applied to keratinocyte or fibroblast cultures. To
increase transfer efficacy, ultracentrifugation was performed to
concentrate the VSV-G virus particles. The titer of the viral
supernatant was determined by real-time quantitative PCR (Towers
et al., 1999).
Cells infection with retrovirus
Keratinocytes and fibroblasts were cultured to up to 60% of
confluency and then infected with the viral suspensions in 5mg/ml
polybrene. To increase the virus–cell interactions, we coated the
surface of the culture plates with 10 ng/ml retronectin (Takara;
fibronectin fragment CH-296). After incubation for 24 hours at 321C,
we maintained the treated cells under fresh medium for another
24 hours until the transduction efficiency was assessed by immuno-
fluorescence examination of the infected cells.
Immunostaining and immunoblot
Transfected cultured keratinocytes and fibroblasts were fixed with
2% parafromaldehye in phosphate-buffered saline, and were then
incubated with the monoclonal antibody LH7.2 (1:100) against the
NC1 domain of collagen VII (Chemicon, Temecula, CA) for 18 hours
at 41C. They were treated with secondary goat anti-mouse IgG
antibodies conjugated with FITC (1:50) for 1 hour at 371C, and
preparations were examined under a fluorescence microscope.
Nuclei were counterstained with propidium iodide (Dojindo
Laboratories, Kumamoto, Japan). Subconfluent cell cultures were
fed for 48 hours with serum-free medium supplemented with 50mg/ml
ascorbic acid. For SDS-PAGE analysis, the culture medium was
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treated with Amicon Ultra-100,000 Centrifugal Filter Devices
(Millipore, Bedford, MA) for concentration and desalting. The
samples were separated on a 5% polyacrylamide gel under reducing
conditions. Immunoblotting analysis was performed by treating with
the LH7.2 monoclonal antibody (1:1,000) for 18 hours at 41C, and
then secondary goat anti-mouse IgG antibodies conjugated with
peroxidase (1:2,000) for 1 hour at 371C. The resultant complexes
were processed for Phototope HRP Western Blot Detection System
(Cell Signaling, Beverly, MA) according to the manufacturer’s
protocol.
Southern blot analysis
The average copy number per cell of the COL7A1 cDNA was
evaluated by Southern blot analysis (Baldeschi et al., 2003). Briefly,
genomic DNA was extracted from subconfluent cell cultures and
digested with BglII and HindIII. Plasmid pDON(D)-COL was serially
diluted with yeast genomic DNA at the final concentration ranging
from 0.5 to 20 copies/cell. The digested DNA was electrophoresed
on a 0.8% agarose gel and transferred to Zeta-Probe membrane
(Bio-Rad, Hercules, CA). The 375 bp cDNA extending from exons
58 to 64 was generated by PCR amplification of COL7A1 cDNA
as a template. This fragment was designed to recognize a
7.2 kb band from the integrated cDNA, and also 1.0 and 0.3 kb
bands from the intrinsic COL7A1 gene. The membranes were
hybridized with the 375 bp cDNA probe was labeled by random
primed incorporation of digoxigenin-labeled 20-deoxyuridine
50-triphosphate using the DIG DNA Labeling Kit (Roche, Indiana-
polis, IN) according to the manufacturer’s instructions. After high
stringency washes, blots were visualized using an enhanced
chemiluminescence system.
Grafting of gene-transferred DEB cells
Gene-transferred and untreated DEB keratinocytes and DEB fibro-
blasts were cultured using the above methods. Fibroblasts (106) were
seeded into a collagen sponge scaffold and maintained in DMEM
with 10% FCS for 3 days. In nude rats (F344/N Jcl-rnu), the sites for
transplantation were prepared by excising a 2 cm2 area of dorsal
epidermis and dermis, and then the collagen sponge (3 cm2)
containing the fibroblasts was placed into the skin wound. The
confluent cultures of 106 keratinocytes were treated with dispase
(1 nU/ml; Godo Shusei, Tokyo, Japan), and the floating epidermal
sheet placed on the collagen sponge. Preliminary experiment
showed that the number of fibroblasts was almost equal to that of
keratinocytes when we applied the graft to the animal. An occlusive
dressing was quickly placed over the graft to hold it in position and
to prevent it from drying out and then the dressing was removed after
7 days. We prepared combinations of gene-transferred keratinocytes
and untreated fibroblasts, of untreated keratinocytes and gene-
transferred fibroblasts, and of untreated keratinocytes and fibroblasts
as control. Skin biopsies were taken from the grafted skin at various
time points and subjected to routine immunohistochemical staining
using the LH7.2 monoclonal antibody and ultrastructural analysis.
To semiquantify COL7A1 accumulation in basement membrane
zone, we converted color images to gray-scale images, and
measured fluorescence intensity (arbitrary scale) in basement
membrane zone at 10 areas using NIH Image software. The COL7A1
deposition index was expressed as the mean7SD from the 10
values.
CONFLICT OF INTEREST
The authors state no conflict of interest.
ACKNOWLEDGMENTS
We wish to thank Dr James R McMillan for proof reading and comments
concerning this manuscript. This work was supported in part by Grants-in-Aid
from the Ministry of Education, Science, Sports, and Culture of Japan to D
Sawamura (15390337, 17659331) and H Shimizu (15390336, 17209038),
and by grants from the Ministry of Health of Japan to H Shimizu (H13-Specific
Disease-02, H16-Intractable Disease-05).
REFERENCES
Baldeschi C, Gache Y, Rattenholl A, Bouille P, Danos O, Ortonne JP et al.
(2003) Genetic correction of canine dystrophic epidermolysis bullosa
mediated by retroviral vectors. Hum Mol Genet 12:1897–905
Burgeson RE (1993) Type VII collagen, anchoring fibrils, and epidermolysis
bullosa. J Invest Dermatol 101:252–5
Chen M, Costa FK, Lindvay CR, Han YP, Woodley DT (2002a) The
recombinant expression of full-length type VII collagen and characteri-
zation of molecular mechanisms underlying dystrophic epidermolysis
bullosa. J Biol Chem 277:2118–24
Chen M, Kasahara N, Keene DR, Chan L, Hoeffler WK, Finlay D et al. (2002b)
Restoration of type VII collagen expression and function in dystrophic
epidermolysis bullosa. Nat Genet 32:670–5
Christiano AM, Greenspan DS, Hoffman GG, Zhang X, Tamai Y, Lin AN et al.
(1993) A missense mutation in type VII collagen in two affected siblings
with recessive dystrophic epidermolysis bullosa. Nat Genet 4:62–6
Christiano AM, Greenspan DS, Lee S, Uitto J (1994a) Cloning of human type
VII collagen, complete primary sequence of the alpha 1(VII) chain and
identification of intragenic polymorphisms. J Biol Chem 269:20256–62
Christiano AM, Hoffman GG, Chung-Honet LC, Lee S, Cheng W, Uitto J et al.
(1994b) Structural organization of the human type VII collagen gene
(COL7A1), composed of more exons than any previously characterized
gene. Genomics 21:169–79
Ghazizadeh S, Taichman LB (2000) Virus-mediated gene transfer for
cutaneous gene therapy. Hum Gene Ther 11:2247–51
Heinonen S, Mannikko M, Klement JF, Whitaker-Menezes D, Murphy GF,
Uitto J (1999) Targeted inactivation of the type VII collagen gene
(Col7a1) in mice results in severe blistering phenotype: a model for
recessive dystrophic epidermolysis bullosa. J Cell Sci 112:3641–8
Krueger GG (2000) Fibroblasts and dermal gene therapy. Hum Gene Ther 11:
2289–96
Ortiz-Urda S, Lin Q, Green CL, Keene DR, Marinkovich MP, Khavari PA
(2003) Injection of genetically engineered fibroblasts corrects regene-
rated human epidermolysis bullosa skin tissue. J Clin Invest 111:251–5
Ortiz-Urda S, Thyagarajan B, Keene DR, Lin Q, Fang M, Calos MP et al.
(2002) Stable nonviral genetic correction of inherited human skin
disease. Nat Med 8:1166–70
Pulkkinen L, Uitto J (1999) Mutation analysis and molecular genetics of
epidermolysis bullosa. Matrix Biol 18:29–42
Rheinwald JG, Green H (1975) Serial cultivation of strains of human
epidermal keratinocytes: the formation of keratinizing colonies from
single cells. Cell 6:331–43
Roth DA, Tawa NE Jr, O’Brien JM, Treco DA, Selden RF (2001) Factor VIII
Transkaryotic Therapy Study Group: nonviral transfer of the gene
encoding coagulation factor VIII in patients with severe hemophilia A.
N Engl J Med 344:1735–42
Ryynanen J, Sollberg S, Parente MG, Chung LC, Christiano AM, Uitto J (1992)
Type VII collagen gene expression by cultured human cells and in fetal
skin, abundant mRNA and protein levels in epidermal keratinocytes.
J Clin Invest 89:163–8
Sawamura D, Yasukawa K, Kodama K, Yokota K, Sato-Matsumura KC, Toshihiro
T et al. (2002) The majority of keratinocytes incorporate intradermally
injected plasmid DNA regardless of size but only a small proportion of
cells can express the gene product. J Invest Dermatol 118:967–71
www.jidonline.org 771
M Goto et al.
COL7A1 Gene Transfer
Towers GJ, Stockholm D, Labrousse-Najburg V, Carlier F, Danos O, Pages JC
(1999) One step screening of retroviral producer clones by real time
quantitative PCR. J Gene Med 1:352–9
Uitto J, Chung-Honet LC, Christiano AM (1992) Molecular biology and
pathology of type VII collagen. Exp Dermatol 1:2–11
Uitto J, Pulkkinen L (2001) Molecular genetics of heritable blistering
disorders. Arch Dermatol 137:1458–61
Vogel JC (2000) Nonviral skin gene therapy. Hum Gene Ther 11:2253–9
Woodley DT, Keene DR, Atha T, Huang Y, Ram R, Kasahara N et al. (2004)
Intradermal injection of lentiviral vectors corrects regenerated human
dystrophic epidermolysis bullosa skin tissue in vivo. Mol Ther 10:
318–326
Woodley DT, Krueger GG, Jorgensen CM, Fairley JA, Atha T, Huang Y et al.
(2003) Normal and gene-corrected dystrophic epidermolysis bullosa
fibroblasts alone can produce type VII collagen at the basement
membrane zone. J Invest Dermatol 121:1523–747
772 Journal of Investigative Dermatology (2006), Volume 126
M Goto et al.
COL7A1 Gene Transfer
